LA-ADTRAN
15.8.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that PhireLink has deployed its open and intelligent fiber access technology to bring high-quality broadband to some of Louisiana’s most underserved rural communities. The deployment features Adtran’s Mosaic One software-as-a-service and its Intellifi® connected home solution to support a robust end-user experience. Using Adtran’s AI-driven platform, PhireLink is rapidly scaling a highly efficient, future-facing network capable of delivering critical public services, such as remote learning and telemedicine, and stimulating economic growth across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815958625/en/
Adtran’s networking technology is helping PhireLink deliver high-speed broadband to rural communities across Louisiana. (Photo: Business Wire)
“We selected Adtran for its open, scalable technology. Our new solution helps us bring dependable, high-speed broadband to more rural communities across Louisiana,” said Glen F. Post, III, CEO of PhireLink. “Working in close collaboration with Adtran’s team, we are not just constructing a network. We’re taking a crucial step towards bridging the digital divide, providing the broadband access needed to invigorate local economies and drive sustained improvements in quality of life.”
Mosaic One empowers PhireLink to enhance operational efficiency, minimize the need for on-site visits, and effectively engage with communities by utilizing materials tailored to local market needs. The end-to-end Combo PON solution also features Adtran’s scalable 10Gbit/s optical line terminal and its SDX 600 Series optical network terminals. What’s more, Adtran’s connected home solution, Intellifi®, is being harnessed in combination with Adtran’s SDG 800 Series Wi-Fi 6 gateways to provide a comprehensive in-home Wi-Fi experience. PhireLink’s customer service representatives can use the platform to resolve connectivity issues remotely, further streamlining operations and ensuring an exceptional customer experience.
“Bridging the digital divide isn’t just a case of deploying the latest and greatest hardware and software. You also need to work closely with clients to overcome challenges unique to each deployment. This is where Adtran excels. We listen to what our clients need and respond with tailored solutions that get the best out of our innovation and give subscribers a great user experience,” commented John Scherzinger, GM of Americas sales at Adtran. “Working closely with PhireLink, we’ve ensured more people in the Slidell area have access to fast and reliable fiber-based internet. But it doesn’t end there. Our Intellifi® cloud-managed Wi-Fi platform enables subscribers to gain better control, personalize and secure their Wi-Fi networks.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About PhireLink
PhireLink is a broadband internet service provider delivering high-quality, high-speed internet across rural America. At PhireLink, we’re more than just an internet provider — we’re neighbors, dedicated to bringing the power of high-speed connectivity to every corner of the communities we serve. We're driven by one simple goal: level the playing field and ensure everyone, no matter where they live, has access to the limitless opportunities the internet provides. To learn more, visit PhireLink.com.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815958625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
